ZIVO Bioscience Cash Flow from Financial Activities 2016-2025 | ZIVO

ZIVO Bioscience cash flow from financial activities from 2016 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities

ZIVO Bioscience Cash Flow from Financial Activities 2016-2025 | ZIVO

ZIVO Bioscience cash flow from financial activities from 2016 to 2025. Cash flow from financial activities can be defined as the net amount of cash transactions used in funding activities
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$213.3B
Amgen (AMGN)$158.5B
Gilead Sciences (GILD)$134.6B
Vertex Pharmaceuticals (VRTX)$118.1B
Bristol Myers Squibb (BMY)$96.4B
CSL (CSLLY)$81.2B
GSK (GSK)$74.3B
Regeneron Pharmaceuticals (REGN)$58.6B
Alnylam Pharmaceuticals (ALNY)$41.8B
Argenex SE (ARGX)$34.6B
BioNTech SE (BNTX)$26.4B
Royalty Pharma (RPRX)$20B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.3B
Illumina (ILMN)$15.2B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$14B
Incyte (INCY)$13.1B
Exelixis (EXEL)$12.1B
Moderna (MRNA)$12.1B
BioMarin Pharmaceutical (BMRN)$11B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.4B
Exact Sciences (EXAS)$9.5B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.2B
Roivant Sciences (ROIV)$7.8B
Legend Biotech (LEGN)$7.6B